Every other pharmaceutical company on this page diversifies across therapeutic areas. Galderma bets everything on skin. Founded in 1981, the Swiss dermatology specialist went public in 2024 and posted record revenue of $5,207 million in 2025, growing at 17.7 per cent on a constant-exchange-rate basis. It is the fastest growth rate among OPPI member companies.
Skin is the largest organ of the human body, and Galderma is the only major pharmaceutical company that treats nothing else. The strategic logic is counterintuitive. In an industry where diversification is considered prudent, where companies spread risk across oncology, immunology, cardiovascular, and neuroscience, Galderma has spent 45 years going deeper into a single organ system. The result is a company that understands dermatology with a specificity that diversified competitors cannot match.
The business divides into three segments that, together, cover the full spectrum of skin care. Injectable aesthetics, anchored by Restylane (hyaluronic acid fillers) and Sculptra (a poly-L-lactic acid bio-stimulator), serves the cosmetic dermatology market. Dermatological skincare, dominated by Cetaphil, is the consumer-facing franchise that generates brand recognition in pharmacies and drugstores worldwide. And therapeutic dermatology, including Differin and Epiduo for acne, addresses prescription skin conditions. Few other companies straddle the line between aesthetics, consumer skincare, and prescription therapeutics. Galderma does it because all three live on the same organ.
Revenue tells the story of a company whose focus has been rewarded. From $3,760 million in 2022 to $4,082 million in 2023 (8.5 per cent CER growth) to $4,410 million in 2024 (9.3 per cent CER growth) to $5,207 million in 2025 (17.7 per cent CER growth). That acceleration, from single-digit to near-double-digit to mid-teen growth, is not typical of a 45-year-old company. Something changed.
Restylane was one of the first hyaluronic acid dermal fillers approved anywhere in the world, and it remains one of the most widely used. The product line has expanded from a single filler into a family of formulations designed for different facial areas: lips, cheeks, jawline, under-eye hollows, and fine lines. Each variant uses a different particle size and crosslinking technology to achieve specific rheological properties. The science is more sophisticated than the popular perception of fillers might suggest.
Sculptra operates on a different principle entirely. Rather than filling volume immediately, it stimulates the body’s own collagen production over a series of treatments. The results develop gradually and last longer than hyaluronic acid fillers. For Galderma, Sculptra represents a higher-value, higher-loyalty product: patients who start a Sculptra treatment course tend to return for maintenance sessions, creating a recurring revenue stream that more closely resembles a subscription model than a one-time purchase.
The injectable aesthetics segment is the growth engine behind Galderma’s acceleration. The global medical aesthetics market has been expanding at rates that outpace most pharmaceutical categories, driven by demographic trends (aging populations with disposable income), social media normalisation of cosmetic procedures, and geographic expansion into markets where aesthetic treatments were previously unavailable. Galderma’s 17.7 per cent CER growth in 2025 reflects, in part, the structural tailwinds of this market. But it also reflects a company that arrived early and invested consistently in training dermatologists and plastic surgeons on injection technique, building a clinical education infrastructure that serves as a commercial moat.
Cetaphil is not a pharmaceutical product. It is a skincare brand that happens to be owned by a pharmaceutical company, and that distinction matters. Developed in 1947 by a pharmacist and acquired by Galderma, Cetaphil is one of the most recommended skincare brands by dermatologists worldwide. The product line, anchored by the original Gentle Skin Cleanser, has expanded into moisturisers, sunscreens, and baby care. It is sold in pharmacies, supermarkets, and online retailers across more than 90 countries.
For Galderma, Cetaphil provides something that most pharmaceutical companies lack: a consumer brand with genuine dermatologist endorsement. The brand trades on clinical credibility rather than celebrity endorsement. When a dermatologist recommends Cetaphil to a patient with sensitive skin, that recommendation carries the weight of medical authority. The result is a brand that competes in the consumer skincare market but draws its competitive advantage from the pharmaceutical channel. It is an unusual hybrid, and it generates significant revenue that does not depend on patent protection, regulatory exclusivity, or insurance reimbursement.
For all its success in aesthetics and consumer skincare, Galderma’s future may hinge on a molecule called nemolizumab. It is a monoclonal antibody that blocks interleukin-31, a cytokine that drives the itch and inflammation in atopic dermatitis and prurigo nodularis. If approved, nemolizumab would give Galderma its first biologic, moving the company from a small-molecule and device-based portfolio into the high-value, high-complexity world of injectable biologics.
The stakes are considerable. Atopic dermatitis is one of the largest and fastest-growing therapeutic markets in dermatology, with existing biologics like dupilumab (Dupixent, from Sanofi and Regeneron) generating tens of billions in annual revenue globally. Galderma does not need to capture the entire market. It needs to demonstrate that a pure-play dermatology company can develop, manufacture, and commercialise a biologic, something it has never done before. Success would validate the pure-play model at the highest level of pharmaceutical complexity. It would also provide a growth engine that could sustain the company’s revenue trajectory well beyond what aesthetics and consumer skincare alone can deliver.
The workforce has expanded alongside the pipeline ambition: 6,500 employees in 2023, 7,000 in 2024, and 7,600 in 2025. Galderma is hiring, and the hiring pattern suggests a company that expects its product portfolio to grow more complex, not simpler, in the years ahead.
Sources: Galderma Group annual reports and IPO prospectus 2022–2025. SIX Swiss Exchange filings. OPPI member directory.